Key result
Early exogenous insulin shows potential cardiovascular and pathophysiologic benefits in Type 2 diabetes.
Answers are grounded in this paper and cite their sources.
John Nicasio DO1 & Samy I McFarlane MD, MPH, FACP, FACE, CCD2† †Author for correspondence 1Assistant Professor of Research, SUNY-Downstate and Kings County Hospital Center, Division of Endocrinology, Diabetes and Hypertension, NY, 11203, USA 2†Associate Professor of Medicine, Interim Chief, Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Box 50, State University of New York, Health Science Center at Brooklyn, Kings County Hospital Center 450 Clarkson Avenue Brooklyn, New York, 11203 USA Tel.: +1 718 270 3711 Fax: +1 718 270 6358 smcfarlane@downstate.edu ‘...there are favorable indications towards cardiovascular prevention and pathophysiologic benefits for initial exogenous insulin administration in Type 2 diabetic patients.’
No takes yet. Share an insight, caveat, or question.
Nicasio et al. (2005) conducted an editorial in Type 2 diabetes. Early exogenous insulin therapy was evaluated on Cardiovascular disease risk. Initial exogenous insulin administration shows favorable indications for cardiovascular prevention and pathophysiologic benefits in patients with Type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: